1-4 of 4
Ryan J. Caddell
Close
Sort by
Journal Articles

Comparison of Liposomal Daunorubicin and Cytarabine Versus Cladribine and High-Dose Cytarabine-Based Induction Chemotherapy in Secondary Acute Myeloid Leukemia Patients (sAML) or Acute Myeloid Leukemia with Myelodysplastic Related Changes (AML-MRC)

Ariel Denson, Ryan J. Caddell, Katherine A. Richter, Jiannong Li, Kendra Sweet, Andrew T. Kuykendall, Eric Padron, Rami S. Komrokji, Jeffrey E. Lancet, Chetasi Talati, David A. Sallman
Journal: Blood
Blood (2021) 138 (Supplement 1): 1258.
https://doi.org/10.1182/blood-2021-151303
Published: 2021
Journal Articles

Evaluation of Dose-Adjusted EPOCH-R Compared with R-CHOP for the Treatment of High-Risk, Aggressive B-Cell Lymphomas: A Single-Center Experience

Sarah J. Rockwell, BS,PharmD, Katherine A. Richter, PharmD, MBA, BCOP, Ryan J. Caddell, PharmD, BCOP, Julio C. Chavez, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-140085
Published: 2020
Journal Articles

Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia

Chetasi Talati, MD, Ryan J Caddell, PharmD, BCOP, Katherine Tobon, PharmD, Rami S. Komrokji, MD, Andrew T Kuykendall, MD, Eric Padron, MD, Hugo F. Fernandez, MD, Alan F. List, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2636.
https://doi.org/10.1182/blood-2019-129166
Published: 2019
Journal Articles

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Ryan J Caddell, PharmD, BCOP, Hayder Saeed, MD, Rebecca Nelson, PharmD, BCOP, Leidy Isenalumhe, MD, Julio Chavez, Celeste Bello, MD, Javier Pinilla Ibarz, MD PhD, Lubomir Sokol, MD PhD, Bijal Shah, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5292.
https://doi.org/10.1182/blood-2019-128435
Published: 2019